Islamabad, Mar 2025: The Drug Regulatory Authority of Pakistan (DRAP) has initiated an urgent recall of multiple pharmaceutical products after detecting impurities in various batches, raising serious concerns over drug quality and patient safety.
The decision follows multiple complaints from provincial health departments and the senior drug inspector of Islamabad Capital Territory (ICT), prompting swift regulatory action against substandard, falsified, and potentially hazardous medicines and medical devices.
According to DRAP, drug testing laboratories in Lahore and Rawalpindi confirmed that several medicines and medical supplies failed to meet quality standards, leading to their immediate withdrawal.
The affected products include Ame-Pin injection (Ameer Pharma), Aqua-P injection (Ipram International), Flagyl Infusion (Sanofi-Aventis).
Metroin Infusion (Saturn Pharmaceuticals), Euro-Flow Cannula (Euromed), Rudazole Injection (Rukha Pharmaceutical), Safemed Injection (Ahad International), and Pulmowell syrup (Vital Phyto Pharma).
Regulators flagged these products due to impurities that could compromise their effectiveness and patient safety. As a result, pharmaceutical manufacturers have been directed to recall all affected batches immediately.
READ MORE:
Barkat Frisian Agro Limited to Make PSX Debut Tomorrow
Suppliers must also provide inventory details to local drug inspectors to facilitate the swift removal of contaminated batches from the market.
Drug Regulatory Authority of Pakistan (DRAP) has issued a stern warning that the continued use of these substandard medicines could lead to treatment failure and severe health complications, particularly for children, the elderly, and immunocompromised patients.
In response, the regulator has launched a nationwide crackdown, instructing the National Regulatory Field Force (NRFF) and provincial drug control departments to take immediate action.
Regulatory teams will conduct market inspections to ensure the removal of defective medicines from pharmacies, medical stores, and healthcare facilities.
DRAP has reaffirmed its commitment to strict enforcement against non-compliance and has urged all stakeholders to cooperate in eliminating these products from circulation to protect public health.
